PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Conditions:   Follicular Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma;   Indolent Lymphoma;   Refractory B-Cell Lymphoma;   MALT Lymphoma Intervention:   Drug: PSB202 Sponsor:   Qilu Puget Sound Biotherapeutics (dba Sound Biologics) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials